NIOX Group (NIOX) Fair Value & Analysis
Healthcare · GB · Market cap 247M GBX
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 22 days ago
Share price +9.0% over the past month.
A strong business, but screening 37% overvalued on our models.
What matters now
- A high-quality business (quality 84/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (£0.4600). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range £0.2369 – £0.6891 · fair‑value band £0.2700 – £0.4600 · the £0.5860 price screens above the £0.3700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
NIOX Group (NIOX) currently trades at £0.5860, while our model-based Fair Value estimate is £0.3700, implying the stock looks roughly 36.9% overvalued today. The Quality Score stands at 84/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, NIOX Group generated revenue of £48.7M at a net margin of 14.4%. Revenue grew 20.0% year over year. It earns a return on equity of 11.0%. The balance sheet holds a net cash position of £18.9M. Fundamentals as of Jul 19, 2026
Our scenario range runs from £0.2700 (bear case) to £0.4600 (bull case); at £0.5860, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -37%, NIOX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (£0.5100) versus Asset-Based (£0.1200). Highest evidence: Residual Income (76).
Notify me when NIOX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 82 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide.
Full company description
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NIOX Group reported revenue of £48.7M in FY2025 versus £27.9M in FY2021, a compound +14.9%/yr. Reported net income was £7.0M in FY2025, compounding +18.1%/yr from FY2021.
NIOX screens 37% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare NIOX Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NIOX Group (NIOX) overvalued or undervalued?
What is the fair value of NIOX?
What is the quality score of NIOX?
What is the revenue of NIOX Group (NIOX)?
What is the net profit margin of NIOX?
Does NIOX Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track NIOX Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.